Sacral Nerve Stimulation Devices Market Report 2024

Where is the largest and fastest growing market for sacral nerve stimulation devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The sacral nerve stimulation devices market size has grown rapidly in recent years. It will grow from $1.19 billion in 2023 to $1.33 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth during the historic period can be attributed to several factors, the increasing prevalence of urinary and fecal incontinence, advancements in neuromodulation technology, rising awareness of non-surgical treatment options, favorable reimbursement policies, a growing geriatric population, higher incidences of neurological disorders, and increased healthcare spending.

The sacral nerve stimulation devices market size is expected to see rapid growth in the next few years. It will grow to $2.08 billion in 2028 at a compound annual growth rate (CAGR) of 11.7%. The growth during the forecast period can be attributed to several factors, improvements in reimbursement policies, greater acceptance of neuromodulation therapies, increasing preference for non-invasive or minimally invasive treatments, exploration of sacral nerve stimulation devices, rising preference among patients and healthcare providers, favorable regulatory environments, and growing global healthcare expenditure. Key trends expected to influence the market include advances in miniaturization and implantable technologies, ongoing exploration of sacral nerve stimulation devices, development of external sacral nerve stimulation devices, enhanced patient education and awareness, regulatory advancements, improved market access, and the integration of spinal cord stimulation or peripheral nerve stimulation technologies.

The growing prevalence of urological disorders is expected to boost the sacral nerve stimulation devices market. Urological disorders include various conditions affecting the urinary tract, kidneys, bladder, and prostate, ranging from acute to chronic. These disorders can be caused by multiple factors, including lifestyle issues such as poor diet, dehydration, and lack of exercise, which can contribute to kidney stones and other painful urinary tract conditions. Sacral nerve stimulation devices offer a minimally invasive treatment option for managing conditions such as urinary and fecal incontinence. For example, in April 2024, the National Institute of Diabetes and Digestive and Kidney Diseases reported that, on average, 651,446 individuals aged 65 and older are newly diagnosed with urinary incontinence annually. This growing prevalence of urological disorders is anticipated to drive the demand for sacral nerve stimulation devices.

Companies in the sacral nerve stimulation devices market are focusing on developing advanced products, such as next-generation sacral neuromodulation devices, to improve patient outcomes, enhance device efficacy, and minimize side effects. These cutting-edge devices offer better control and efficiency in stimulating sacral nerves. For instance, in February 2022, Medtronic plc, an Ireland-based medical device company, introduced the InterStim X. This next-generation device is designed for sacral neuromodulation therapy, addressing conditions such as overactive bladder (OAB), chronic fecal incontinence, and non-obstructive urinary retention. The InterStim X offers long-term, personalized treatment without the need for recharging, providing patients with up to a decade or more of therapy, enhancing convenience and adherence.

In January 2024, Boston Scientific Corporation, a US-based biotechnology firm, acquired Axonics for $3.7 billion. This acquisition aims to expand Boston Scientific's medical technology portfolio by integrating Axonics' specialized devices for treating urinary and bowel dysfunction. Axonics Inc., based in the U.S., is known for its implantable sacral neuromodulation (SNM) systems designed to address urinary urge incontinence and urinary urgency frequency (UUF).

Major companies operating in the sacral nerve stimulation devices market are Abbott, Medtronic plc, Boston Scientific Corporation, Livanova, Axonics Modulation Technologies, Laborie Medical Technologies, Beijing PINS Medical Co. Ltd., Nevro Corp., Cala Health, Micro Systems Technologies, Neuspera Medical, EndoStim Inc., InCube Labs, Soterix Medical, Synapse Biomedical Inc, Soin Neuroscience, Nuvectra Corporation, StimGuard LLC, Medzell, General Stim Inc.

North America was the largest region in the sacral nerve stimulation devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sacral nerve stimulation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sacral nerve stimulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A sacral nerve stimulation device is a medical implant that uses electrical impulses to modulate nerves in the sacral area. It is used to treat conditions such as urinary incontinence and overactive bladder by regulating nerve activity, aiming to improve bladder function and enhance the quality of life for patients through targeted neurological intervention.

The main types of sacral nerve stimulation devices include electrical muscle stimulation devices and transcutaneous electrical nerve stimulation (TENS) devices. An electrical muscle stimulation device delivers electrical impulses to muscles via electrodes placed on the skin. Products in this category include external sacral nerve stimulation devices and implantable sacral nerve stimulation devices, which cater to different age groups such as pediatrics, adults, and geriatrics. These devices are used for various applications, including urinary incontinence, fecal incontinence, and other conditions, and are provided through hospitals, ambulatory surgical centers, and specialty clinics.

The sacral nerve stimulation devices market research report is one of a series of new reports that provides sacral nerve stimulation devices market statistics, including sacral nerve stimulation devices industry global market size, regional shares, competitors with a sacral nerve stimulation devices market share, detailed sacral nerve stimulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the sacral nerve stimulation devices industry. This sacral nerve stimulation devices market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sacral nerve stimulation devices market consists of sales of pulse generators, insulated wires, and electrode arrays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.